AIM ImmunoTech Management

Management criteria checks 3/4

AIM ImmunoTech's CEO is Thomas Equels, appointed in Aug 2015, has a tenure of 9.25 years. total yearly compensation is $1.08M, comprised of 78.6% salary and 21.4% bonuses, including company stock and options. directly owns 2.36% of the company’s shares, worth $373.26K. The average tenure of the management team and the board of directors is 8.7 years and 8.3 years respectively.

Key information

Thomas Equels

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage78.6%
CEO tenure9.3yrs
CEO ownership2.4%
Management average tenure8.7yrs
Board average tenure8.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Thomas Equels's remuneration changed compared to AIM ImmunoTech's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$1mUS$850k

-US$29m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$19m

Dec 31 2022US$1mUS$850k

-US$19m

Sep 30 2022n/an/a

-US$21m

Jun 30 2022n/an/a

-US$18m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$2mUS$850k

-US$19m

Sep 30 2021n/an/a

-US$17m

Jun 30 2021n/an/a

-US$17m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$3mUS$807k

-US$14m

Sep 30 2020n/an/a

-US$12m

Jun 30 2020n/an/a

-US$11m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$890kUS$703k

-US$9m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$10m

Mar 31 2019n/an/a

-US$10m

Dec 31 2018US$1mUS$751k

-US$10m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$987kUS$713k

-US$8m

Compensation vs Market: Thomas's total compensation ($USD1.08M) is above average for companies of similar size in the UK market ($USD371.29K).

Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.


CEO

Thomas Equels (71 yo)

9.3yrs

Tenure

US$1,081,301

Compensation

Mr. Thomas K. Equels, Esq. M.S., J.D. serves as Director at BioFlorida Inc since August 2021. He serves as the Chief Executive Officer of AIM ImmunoTech Inc. (formerly known as Hemispherx Biopharma, Inc.)...


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Equels
Executive Vice Chairman9.3yrsUS$1.08m2.36%
$ 373.3k
Robert Dickey
Chief Financial Officer2.6yrsUS$64.48k0%
$ 0
Peter Rodino
COO, Executive Director of Governmental Relations8.1yrsUS$527.64k0.63%
$ 100.3k
Christopher McAleer
Scientific Officer1.9yrsno datano data
Ann Marie Coverly
Director of Administration & Human Resources and Deputy Investor Relations Coordinator11.8yrsno datano data
Ralph Cavalli
Vice President of QC & Manufacturing14.6yrsUS$244.00kno data

8.7yrs

Average Tenure

70yo

Average Age

Experienced Management: 0A4Y's management team is seasoned and experienced (8.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Equels
Executive Vice Chairman16yrsUS$1.08m2.36%
$ 373.3k
Ronald H. Brus
Member of Scientific Advisory Boardno datano datano data
William Mitchell
Independent Chairman of the Board & Member of Scientific Advisory Board26.3yrsUS$139.37k0.12%
$ 19.1k
Christopher Nicodemus
Member of Scientific Advisory Boardno datano datano data
Nancy Bryan
Independent Director1.7yrsUS$93.75k0.061%
$ 9.6k
Stewart Appelrouth
Independent Director8.3yrsUS$139.37k0.38%
$ 59.9k
W. Burnette
Chairman of Scientific Advisory Board1.6yrsno datano data
Philip Roane
Member of Scientific Advisory Boardno datano datano data

8.3yrs

Average Tenure

70yo

Average Age

Experienced Board: 0A4Y's board of directors are considered experienced (8.3 years average tenure).